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Circulating vitamin D metabolite concentrations in childhood renal
diseases. Vitamin D metabolites were measured in children, untreated
with glucocorticoids, who had renal disease. Two groups were defined
in relation to endogenous creatinine clearance values: those with
impaired clearance, 0 to 48 mI/mm per 1.73 m2; and those with
unimpaired clearance, 75 to ISO nil/mm per 1.73 m2. Serum l,25(OH)2D
was 16 (SD) 12 pg/mI in impaired patients (N = 24) and 48 16 pg/mI
in unimpaired patients (N = 18). The latter level is not different from
healthy childhood controls (43 12 pg/mI; N = 194). Serum samples of
25(OH)D2 and D3 were comparable in each group and not different from
control values of 33.2 10.3 ng/ml. Serum 24,25(OH),D was 0.6 (SD)
0.14 ng/ml in patients with a clearance of < 13 mI/mm per 1.73 m2, 1.39
0.54 ng/ml in those with a clearance of 18 to 48 mI/mm per 1.73 m2,
and 1.52 0.91 ng/ml in patients without an impairment of clearance.
Only patients with the lowest clearances had values different from
control values of 1.70 0.57 ng/ml. in our study we suggest that a
significant reduction in 24,25(OH),D and I,25(OH)2D are found at low
clearance values in children with tubulointerstitial disease. Our study
further suggests that a reduction in renal tubular mass is important in
accounting for these changes in vitamin D metabolite values.
Concentrations circulantes des métabolites de Ia vitamine D dans les
affections rénales de l'enfant. Les concentrations des métabolites de Ia
vitamine D ont été mesurées chez des enfants atteints d'affections
rénales non traitées par les glucocorticoIdes. Deux groupes ant été
définis en fonction de Ia clearance de Ia créatinine: Diminuée: de 0 a 48
mi/mm par 1,73 m2. et non diminuée: de 75 a ISO mI/ruin par 1,73 m2. La
concentration sérique de I ,25(OH),D est de 16 (SD) 12 pg/mI dans le
groupe a clearance diminuée (N = 24) et de 48 16 pg/mI dans le
groupe a clearance non diminuée (N = 18). Ce dernier niveau n'est pas
different de celui des enfants sains (43 12 pg/mI; N = 194). Les
concentrations seriques de 25(OH),D et de D sont semblables dans les
deux groupes et non différentes des valeurs contrôles de 33,2 10,3 ng/
ml. La concentration sérique de 24,25(OH)2D est de 0,6 0,14 ng/ml
chez les malades dont Ia clearance set inférieure a 13 mI/mm par 1,73
m2, de 1,39 0,54 mg/mI chez ceux dont Ia clearance est de 18 a 48 ml!
mm par 1,73 m2 et de 1,52 0,91 ng/ml chez ceux dont Ia clearance
n'est pas diminuée. Seuls les malades dont les clearance sont les plus
basses ant des valeurs différentes des contrôles (1,70 0,57 ng/ml).
Dans notre étude nous suggèrons qu'une diminution significative de
24,25(OH)2D et de I ,25(OH)2D est observée quand Ia valeur de Ia
clearance est faible chez les enfants atteints de néphropathie tubuloin-
terstitielle. Notre étude suggère, de plus, qu'une diminution de Ia masse
tubulaire rénale est importante dans le déterminisme de ces modifica-
tions de concentration des métabolites de Ia vitamine D.
tamin D (24,25(OH)2D) [2]. Considering the reduction of neph-
ron mass by chronic renal disease, it is anticipated that the
circulating levels of these two vitamin D metabolites would fall.
Previous reports indicate that calcitriol concentrations are
reduced in both adults [3—7] and in children [8—10] with renal
failure. Little information is available to indicate at what level
of renal function serum calcitriol levels begin to fall [6, II, 12].
Further, there are difficulties in measuring serum 24,25(OH)2D
concentrations in patients with uremia that may give conflicting
results, depending on the assay method chosen [5, 13, 14].
Our study describes the serum concentration of calcitriol in
42 samples from 37 children with renal disease. Also included in
the study is a wide spectrum of serum creatinine concentrations
and creatinine clearance values. In many of these patients,
simultaneous measurements of serum 25(OH)D2 and D3 and
24,25(OH)2D are available. Our data suggest that calcitriol
concentrations fall gradually as renal function becomes re-
duced. Deficiency of 25(OH)D was not evident in these children
living in the Midwest of the United States. Serum concentration
of 24,25(OH)2D was significantly decreased at low clearance
values. Our study indicates that only during a severe reduction
of clearance are significantly abnormal concentrations of vita-
min D metabolites found.
Methods
All patients were observed in the Pediatric Renal Disease
Clinic of the University of Wisconsin Hospitals. Patients were
between 14 months and 18 years of age. Excluded from this
study were patients receiving chronic glucocorticoid therapy
[15], who had diabetes mellitus or systemic lupus erythemato-
sus, an inborn error of calcium and phosphate metabolism, or
an uncomplicated urinary tract infection or enuresis. Patient
diagnoses, listed in Table I, were made by appropriate radiolog-
ic, histologic, immunologic, and biochemical diagnostic proce-
dures. Patients classified as having tubulointerstitial disease
had cystinosis, oxalosis, the Fanconi syndrome, obstructive
The lc-hydroxylation of 25-hydroxyvitamin D (25(OH)D)
occurs in mitochondria in the renal proximal tubule, producing
the hormonally active form of vitamin D—l ,25-dihydroxyvita-
mm D or calcitriol [I]. Renal tissue is also the major site of
production of another vitamin D analogue—24,25-dihydroxyvi-
65
Received for publication October 27, 1980
and in revised form May 19, 1981
0085-2538/82/0021-0065 $01.00
© 1982 by the International Society of Nephrology
66 Chesnev et al
Table 1. Diagnoses of patients studied and number of samples
obtained from each disease type
Degree of impaired creatinine clearance No. of patients
Severely (0 to 13 mI/mm per 1.73 in2)
Cystinosis 3
Posterior urethral valves 3
Infantile polycystic kidneys 2
Fanconi syndrome I
Alport syndrome I
Renal hypoplasia 3
Refiux nephropathy with dysplasia 2
Total /5
Moderately (/8 to 48 mI/mm per 1.73 m2)
Reflux nephropathy with dysplasia 3
Chronic glomerulonephritis 2
Obstructive uropathy 2
Membranoproliferative glomerulonephritis I
Oxalosis I
Total 9
Mildly (75 to /50 mI/mm per 1.73 m2)
Berger's disease 3
Benign recurrent hematuria 5
Membranoproliferative glomerulonephritis 3
Familial C4 deficiency with
glomerulonephritis I
Alport syndrome I
Undifferentiated glomerulonephritis 2
Idiopathic nephrotic syndrome 2
Henoch-Schonlein purpura I
Total /8
uropathy, renal hypoplasia, congenital dysplasia, chronic inter-
stitial nephritis (reflux nephropathy), and infantile polycystic
renal disease. Those patients with glomerular disease had
minimal lesion nephrotic syndrome, focal sclerosing glomerulo-
nephritis, membrano-proliferative glomerulonephritis, chronic
undifferentiated glomerulonephritis, Henöch-Schonlein purpu-
ra, Berger's disease, and benign familial and non-familial hema-
tuna. Patients with the Alport syndrome were arbitrarily as-
signed to the tubulointerstitial disease group.
Blood samples were obtained from patients who fasted
for the measurement of creatinine, 25(OH)D2, 25(OH)D1,
24,25(OH)2D, and calcitniol. These samples were obtained in
children on an outpatient visit while eating their regular diet. In
a preliminary report, the calcitriol values were given in six of
these children 18].
The values obtained for vitamin D metabolites were com-
pared to values from healthy control subjects 18 months to 20
years of age. The method for obtaining blood samples from
these healthy children is described elsewhere [101 and involves
obtaining samples from children undergoing elective surgery,
such as herniorrhaphy, tonsillectomy, or strabismus repair. In
the control subjects, 108 blood samples (56%) were obtained
from children less than 10 years of age and 86 samples (44%)
from children older than 10 years. Among the patients, 20 blood
samples (48%) were obtained from children less than 10 years
old and 22 samples (52%) from older children.
Ten of the children with the lowest values for creatinine
clearance (0 to 9 mI/mm per 1 .73 m2) had radiologic evidence of
renal osteodystrophy of varying extent. Each patient had
radiologic changes including a delayed bone age for chronologic
age, metaphyseal widening and fraying at the ends of long
bones, and subperiosteal erosions evident when hand phalanges
were examined. These patients were treated with aluminum
hydroxide containing phosphate sequestering agents and oral
calcium lactate or carbonate. The patients also received a daily
high dosage of ergocalciferol (8 pts) or dihydrotachysterol (2
pts) before being treated with calcitriol. These vitamin D
compounds were discontinued 30 days before initiating calci-
triol therapy.
Endogenous creatinine clearance, corrected to 1.73 m2 sur-
face area, was ascertained by the method of Schwartz et al [16].
Briefly, this technique is based on the patient's length and
serum creatinine concentrations, correlating highly with an
inulin clearance determined in a metabolic unit.
Circulating vitamin D metabolites were measured by a pre-
cise assay using 6.0 ml of a serum sample to provide determina-
tions in triplicate. The assays used are described in detail
elsewhere [4, 51, involving the use of high-pressure liquid gas
chromatography after lipid extraction, Assays were performed
in parallel with known reference standards of each metabolite to
confirm reproductibility. The presence of other vitamin D
metabolites does not interfere with the measurement of
24,25(OH)2D in this assay. Assay precision for 25(OH)D is 5
ng/ml. For 24,25(OH),D, it is 0.1 ng/ml, and for calcitriol, it is
2 pg/mI. Values in normal children are: 7.3 5.2 (SD) ng/ml
for 25(OH)D2 (N = 2l); 23.2 8.7 ng/ml for 25(OH)D3 (N =
21); and 30.5 9.7 ng/ml for total 25(OH)D (N = 21); 1.70
0.47 ng/ml for 24,25(OH)2D (N 28); and 43 12 pg/mI for
calcitriol (N = 194).
Data were analyzed by linear regression analysis or by
Student's t test. Data are usually presented as mean SD.
Results
Based on serum creatinine concentration and endogenous
creatinine clearance level, patients were placed into one of two
groups for evaluating calcitriol concentrations. Patients with an
impairment of renal function had an endogenous creatinine
clearance of 18 14 mI/mm per 1.73 m2 with a range ofO to 48
mI/mm per 1.73 m2. The 24 patients largely have congenital
tubulointerstitial diseases, including posterior urethral valves,
hypoplasia, and dysplasia, although 3 patients had chronic
glumerulonephritis. The other patients have clearance values of
75 to 150 mI/mm per 1.73 m2 (mean of 97 7 mI/mm per 1.73
m2). The latter mentioned children have benign recurrent
hematuria, Berger's disease, and nephrotic syndrome.
The serum creatinine concentrations for each group were: 8. I
3.6 mg/dl (SD) (range, 2.5 to 14.7 mg/dl; N = 15) for patients
with a clearance of less than 13 mI/mm per 1.73 m2; 2.9 0.6
mg/dl (range, 1.9 to 3.9 mg/dl; N = 15) for patients with a
clearance of 18 to 48 mI/mm per 1.73 m2; and 0.8 0.4 mg/dl
(range, 0.5 to 1.4 mg/dl; N = 18) for patients with a clearance of
75 to 150 mI/mm per 1.73 m2.
The concentrations of calcitriol in relation to corrected
endogenous creatinine clearance are given in Figure 1 and Table
2. The value in patients with impaired creatinine clearance was
16 12 pg/mI (N = 24), significantly below the mean value in
194 healthy control children of 43 12 (SD) pg/mI, P < 0.001.
The concentration in patients with normal creatinine clear-
ance values is 48 16 pg/mI (N = 18). As noted in Figure I, the
value for creatinine clearance is correlated with the circulating
calcitriol concentration by linear regression analysis (r =0.683,
P < 0.001) in patients with impaired creatinine clearance
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Fig. 1. Serum calcitriol in relation to endogenous creatinine clearance
(mi/mm per 1.73 m2). Open circles (0) indicate tubular disease: closed
circles (I) indicate glomerular disease. The diamonds show the values
of "calcitriol-like activity" in 2 anuric patients receiving DHT at
clearance values of < 48 mI/mm per 1.73 m2. Serum calcitriol concen-
tration and clearance are related; y = 0.755x + 6.2, P < 0.001.
Serum
calcitriol
Group N'
Clr
ml/min/l.73 m2
concentration
pg/mi
Healthy controls 194 — 43 12
Clearance below 50
ml/min/l.73 m2 24 18 14
(0 to 48 mI/mm)
16 12
No reduction of clearance 18 99 7
(78 to 150 mI/mm)
48 16
values. All patients in this study with congenital obstructive or
tubulointerstitial disease had a creatinine clearance value of
<48 mI/mm per 1.73 m2. Accordingly, reduced calcitriol levels
were found in those patients with both reduced clearance values
and congenital nonglomerular disease.
Also displayed in Figure 1 are the values for two anuric
children undergoing dialysis who have been treated with 200 g
DHT daily. Calcitriol levels of 44 and 52 pg/mI were obtained
because the presence of DHT or a metabolite of DHT in serum
concentrations is known to compete with the chick intestinal
binding site for calcitriol [17]. Accordingly, calcitriol levels,
even in anuric uremic subjects, are invalid after the administra-
tion of DHT, Further, it is unknown whether a level of 40 to 50
pg/mI is as biologically effective as a comparable level of
calcitriol.
For the evaluation of the concentrations of 25(OH)D and
24,25(OH)2D in serum samples, patients were placed into three
groups: Those with severely impaired creatinine clearance (0 to
13 mI/mm per 1.73 m2), moderately impaired creatinine clear-
ance (18 to 48 mI/mm per 1.73 m2), and little or no impairment of
creatinine clearance (75 to 150 mI/mm per 1.73 m2). The reason
Severe Severe Moderate
Vit. 0 It
Fig. 2. Serum 25(OH)-vitamin Din each group. The upper portion of the
figure shows 25(OH)D3 and the lower portion 25(OH)D2. Note the
markedly elevated 25(OH)D2 levels in patients treated with ergocalci-
ferol. Data are expressed as: mean SEM of total 25(OH)D levels, and
the number indicates the number of patients from whom samples were
taken in each group.
for grouping the patients is to demonstrate the significant
decline in circulating 24,25(OH)2D values with severe impair-
ment in renal function.
The serum concentrations of 25(OH)D are shown in Figure 2.
No patient or control subject had a serum sample of 25(OH)D
concentration less than 16 ng/ml. In our patients, no differences
in 25(OH)D levels were noted between controls and patients
with all levels of renal function, except that the eight patients
with severe reduction of renal clearance previously treated with
high daily doses of ergocalciferol (5,000 to 75,000 IU daily) have
a mean 25(OH)2D concentration of 176 ng/ml one month after
discontinuation of this metabolite. These patients had a signifi-
cantly higher proportion of total 25(OH)D values in the
25(OH)D2 fraction (P < 0.001), and the 25(OH)D2 to 25(OH)D3
ratio is reversed in comparison to controls. Although patients in
the severely affected but nonergocalciferol-treated group have a
higher ratio of 25(OH)D2 to 25(OH)D3, no significant differ-
ences in this D2/D3 ratio were found between these patients and
those in the control and other two patient groups. All groups
had a level of approximately 30 ng/ml, comparable to values
found in many other studies [5].
The circulating concentrations of 24,25(OH),D are given in
Table 3. Only in severely affected patients were 24,25(OH)2D
levels reduced to values less than control, 0.6 0.14 ng/ml (SD)
vs. 1.70 0.57 ng/ml, P <0.001. Prior treatment with ergocal-
ciferol was associated with an increase in 24,25(OH)2D concen-
tration in these patients to 1.41 0.60 nglml (N = 14).
The correlation between serum calcitriol and 24,25(OH)2D is
shown in Figure 3. These levels appear to be directly correlated
by linear regression analysis, P < 0.001.
Discussion
Our study examines the relationship of renal function as
assessed by endogenous creatinine clearance to vitamin D
metabolite concentrations. Because this study is in children,
most patients with a clearance of < 50 mI/mm per 1.73 m2 have
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Table 2. Serum calcitriol concentration in childhood renal diseasea
Mild Control
Values are the mean SD.
N = number of children.
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Sever&'
no Rx
Severe
Rx Moderate Mildd Controls
0.60e 1.41 1.39 1.52 1.70
N=9 N=14 N=4 N=4 N=28
Values are the mean SD.
Severe denotes a clearance of less than 13 mI/mm/I .73 m2.
Moderate denotes a clearance of 18 to 48 mI/mm/I .73 m2.
d Mild denotes a clearance of 75 to ISO ml/min/l.73 m2.
P < 0.001 vs. control.
Rx = therapy with ergocalciferol at doses of 5,000 to 75,000 U per
24 hrs.
I I I I I I I
congenital tubulointerstitial disease. Accordingly, this study
examines vitamin D metabolite values in children with acquired
glomerular disease in comparison to the values in children with
congenital tubular disease.
In the group with a clearance of < 50 mI/mm per 1.73 m2,
there is a direct, statistically significant correlation between
clearance value and calcitriol concentration. It is possible that
the tubular mass of these children is reduced, thus accounting
for the decline in calcitriol concentration, However, the only
available measurement of renal function on these subjects is the
creatinine clearance. In these subjects with tubulointerstitial
disease, it is also clear that 24,25(OH)2D levels are significantly
reduced and are correlated with calcitriol levels. Disease type,
degree of renal impairment, the level of calcitriol, and
24,25(OH)2D do not influence the concentration of 25(OH)D2
and D3 found in these patients. Above a level of 50 mI/mm per
1.73 m2, calcitriol values are normal and are not correlated with
any change in clearance.
Other factors that may influence the values of vitamin D
metabolites include diet, calcium and phosphate intake, and the
ingestion of aluminum hydroxide [1, 6]. The role of aluminum
hydroxide therapy was difficult to assess because many of these
children with low clearance values remained hyperphosphate-
mic.
Some patients with renal osteodystrophy, studied elsewhere
have had a significant reduction in circulating 25(OH)D concen-
trations [18, 191, although most of these reports originate in
Europe where patients have decreased dietary vitamin D in-
take, In our patients, with an intake of vitamin D-fortified milk
and generally ample sunlight exposure, 25(OH)D levels were
comparable at all degrees of renal function. Significant
25(OH)D deficiency is unlikely to be present in children with
renal insufficiency in the United States, unless these children
are eating a bizarre diet. Of interest is that 25(O1-I)D2 levels had
a mean value of 175 ng/ml in 6 patients receiving a high dosage
of ergocalciferol therapy, a value that is nearly 25 times normal;
the ratio of 25(OH)D2/25(OH)D3 is completely reversed in these
patients.
The decrease in serum calcitriol values found in patients
previously treated with ergocalciferol could be related to the
reduction in calcitriol synthesis that follows dosing with vitamin
D or 25(OH)D in both man [21] and rat [23]. With high
circulating levels of 25(OH)D, the synthesis of calcitriol is
reduced. The reduction in calcitriol found in these patients with
renal disease is unlikely to be related to this phenomenon
because the calcitriol value in nonpretreated patients is 12 10
(SD) pg/mI and in ergocalciferol-treated patients it is 17 10 pg/
ml. These values are not statistically different. In addition,
these latter patients were not being dosed with ergocalciferol at
the point that the serum samples were obtained, as occurred in
the studies demonstrating the suppression of calcitriol synthesis
[2!, 22].
Some authors have indicated that 24,25(OH)2D concentra-
tions are normal in uremic individuals [14]. Our data fail to
support this finding. Indeed, we find serum concentrations
comparable to those found by Shepard et al [5]in the plasma of
adult anephric patients. In severely affected patients, the value
is 0.6 0.14 ng/ml, comparable to the reported values in adults
of 0.7 ng/ml. Furthermore, there is a direct correlation between
calcitriol and 24,25(OH)2D concentrations. The discrepancy
between our values and those reported by Haddad et al [14]
may be that his assay is measuring a contaminating metabolite
of vitamin D [20] which nearly co-migrates with 24,25(OH)2D.
This metabolite, which appears to be 25-hydroxyvitamin
D-26,23-lactone [231, can be separated by rechromatography of
the 24,25(OH)2D region using a reverse-phase solvent system
[14], as we have done in our assay [5]. Tayloret al [131 reported
that 24,25(OH)2D is not usually found in anephric subjects,
although several values were in the range of 0.4 to 0.8 ng/ml, not
dissimilar from our findings in severely affected patients. Their
assay will detect values as low as 0.25 ng/ml in comparison to
values as low as 0.15 ng/ml in the assay method of Shepard et al
[5]. But the former assay method does not utilize high-pressure
liquid chromatography [13]. We and Taylor et al [13] found no
correlation between serum 25(OH)D values and 24,25(OH)7D in
severe uremia prior to the initiation of vitamin D therapy. Our
finding of serum values of 0.6 ng/ml in patients with severe renal
impairment indicates that extrarenal sites of 24,25(OH)2D syn-
thesis, including the gut and bone [24, 25], are responsible for
these levels. At clearance values higher than 15 mI/mm per 1.73
m2, no differences in 24,25(OH)2D from control values were
evident. Following therapy with ergocalciferol, we found simi-
lar values to controls. Thus, significant 24,25(OH)2D deficiency
is apparent only with severe impairment of renal function and in
patients with tubulointerstitial disease not treated with ergocal-
ciferol.
Table 3. Concentration of 24,25 (OH)2-vitamin D (ng/ml)a
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Serum 24,25-(OH)2 D,ng/ml
Fig. 3. The relationship ofserum ca/curio! to 24.25(OH)2-vitamin D in
children with renal disease.
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In conclusion, a significant reduction in serum 24,25(OH),D
concentrations are found only at clearance values less than 13
mi/mm per 1.73 m2. The concentration of calcitriol correlates
with creatinine clearance in patients with tubulointerstitial
disease at a clearance level of 50 mI/mm per 1.73 m2 or less. A
recent examination of uremic children using bone histomor-
phometry revealed that the earliest indication of renal osteodys-
trophy appears in patients with a creatinine clearance of < 45
mI/mm per 1.73 m2 [26]. Calcitriol levels in children with
clearances between 18 and 48 mi/mm per 1.73 m2 are compara-
ble to children in our clinic treated with chronic steroids [27, 28]
or with X-linked hypophosphatemic rickets [29]. Our study
indicates that a reduction in renal tubular mass is important in
accounting for these changes in vitamin D metabolite values.
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